SCHEMBL43037

SCHEMBL43037

COCOc1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNA3 P22001 1/20 0.52
CA4 P22748 1/20 0.50
LTA4H P09960 3/20 0.48
HTR1B P28222 2/20 0.46
LMNA P02545 1/20 0.46
HTR1D P28221 1/20 0.46
TAAR1 Q96RJ0 1/20 0.46
ALDH1A1 P00352 1/20 0.46
RECQL P46063 1/20 0.46
AOC3 Q16853 1/20 0.45
ALOX15 P16050 1/20 0.44
CHRNB2 P17787 1/20 0.43
CHRNB4 P30926 1/20 0.43
CHRNA3 P32297 1/20 0.43
CHRNA7 P36544 1/20 0.43
CHRNA4 P43681 1/20 0.43
KCNH2 Q12809 1/20 0.43
DRD2 P14416 1/20 0.42
DRD4 P21917 1/20 0.42
DRD3 P35462 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24313749 0.91 LTA4H (0.63) LTA4H
SCHEMBL2130060 0.86 LSS (0.52) LTA4HLMNAALDH1A1CHRNB2CHRNB4
SCHEMBL3589633 0.86 NQO1 (0.50) LTA4HRECQLMAPT
SCHEMBL497461 0.83 KCNA3 (0.63) KCNA3LTA4HHTR1BLMNAHTR1D
SCHEMBL12772058 0.83 LTA4H (0.64) LTA4H
SCHEMBL1607526 0.82 MAOB (0.48) LMNAALDH1A1
SCHEMBL9369921 0.81 KCNA3 (0.50) KCNA3CA4LTA4HHTR1BHTR1D
SCHEMBL23309720 0.81 LTA4H (0.42) LTA4HALDH1A1MAPT
SCHEMBL9422520 0.81 LTA4H (0.49) LTA4H
Hydrochloric Acid SCHEMBL10519295 0.80 KCNA3 (0.60) KCNA3LTA4HHTR1BLMNAHTR1D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1208 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118290238-A Preparation method of isorhapontin 深圳技术大学 2024-07-05 CN claimed
CN-113620945-A RET inhibitor, pharmaceutical composition thereof and application thereof in medicines 广东东阳光药业有限公司 2021-11-09 CN claimed
US-10224485-B2 Process for preparing a crystalline organic semiconductor material BASF SE (DE) 2019-03-05 US claimed
US-9293711-B2 Organic semiconductor formulations POLYERA CORPORATION (US) 2016-03-22 US claimed
EP-1647262-B2 Anhydrous cosmetic composition comprising electrophilic monomers and acid, and use for cosmetic treatment of hair OREAL (FR) 2012-02-08 EP claimed
EP-1455738-B1 USE OF ELECTROPHILIC MONOMERS FOR HAIR TREATMENT OREAL (FR) 2010-07-28 EP claimed
EP-1647262-B1 Anhydrous cosmetic composition comprising electrophilic monomers and acid, and use for cosmetic treatment of hair OREAL (FR) 2009-08-05 EP claimed
CN-101495657-A Nucleic Acid Amplification Using Reversibly Modified Oligonucleotides WANLI BI (US) 2009-07-29 CN claimed
US-7357921-B2 Hair cosmetic formualtion containing an acrylic or vinyl monomer capable of polymerizing by anionic polymerization in the presence of a nucleophilc agent L'OREAL (FR) 2008-04-15 US claimed
EP-1847252-A2 Composition comprising a cyanoacrylate monomer, a glucidic compound and a liquid organic solvent and cosmetic treatment methods L'Oréal (FR) 2007-10-24 EP claimed
EP-1647264-A1 use for cosmetic treatment of keratinic material of a composition comprising an electrophilic monomer and a non-siloxane polymer, thereby achieving a rigid coating L'OREAL (FR) 2006-04-19 EP claimed
EP-1647265-A1 Use for the cosmetic treatment of keratinous material of non sticky compositions based on electrophilic monomeres and non-silicon polymers L'OREAL (FR) 2006-04-19 EP claimed
EP-1647259-A1 use for treatment of keratinic materials of compositions comprising electrophilic monomers and agents forming liquid crystals L'OREAL (FR) 2006-04-19 EP claimed
EP-1647260-A1 use for cosmetic treatment of keratinic material of a composition comprising an electrophilic monomer and a non-siloxane polymer, thereby achieving a soft coating L'OREAL (FR) 2006-04-19 EP claimed
US-20060078523-A1 Composition comprising at least one electrophilic monomer and at least one acid in a cosmetically acceptable anhydrous medium, and use thereof for cosmetic treatment of the hair L'OREAL S.A. (FR) 2006-04-13 US claimed
US-20060078522-A1 Composition for treating keratin materials comprising at least one electrophilic monomer and at least one salt L'OREAL S.A. (FR) 2006-04-13 US claimed
CN-1604275-A Pattern formation method MATSUSHITA ELECTRIC INDUSTRIAL CO LTD (JP) 2005-04-06 CN claimed
EP-1455738-A2 USE OF ELECTROPHILIC MONOMERS FOR HAIR TREATMENT L'OREAL (FR) 2004-09-15 EP claimed
US-20030175229-A1 Electrophilic monomers for treating the hair L'OREAL (FR) 2003-09-18 US claimed
WO-2003053380-A2 USE OF ELECTROPHILIC MONOMERS FOR HAIR TREATMENT L'OREAL (FR) 2003-07-03 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030175229-A1 Electrophilic monomers for treating the hair NACA, SUCLG1, TYR KCNA3 2840/4885CA4 1543/4885LTA4H 955/4885
US-20060078523-A1 Composition comprising at least one electrophilic monomer and at least one acid in a cosmetically acceptable anhydrous medium, and use thereof for cosmetic treatment of the hair HOGA1, OAT, SUCLG1 KCNA3 4580/4885CA4 1024/4885LTA4H 2227/4885
US-10224485-B2 Process for preparing a crystalline organic semiconductor material STOM, SPOP, TTR KCNA3 2318/4885CA4 43/4885LTA4H 3533/4885
US-20060078522-A1 Composition for treating keratin materials comprising at least one electrophilic monomer and at least one salt KRT18, DSG1, DSC1 KCNA3 343/4885CA4 1016/4885LTA4H 3282/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.